Abstract
Background/aims
Liver fibrosis determined hepatocellular carcinoma (HCC) occurrence in chronic hepatitis C patients with sustained virological response (SVR). We aimed to determine whether post-treatment fibrotic modification overwhelmed pretreatment fibrotic status in terms of long-term HCC prediction.
Methods
265 SVR patients with paired biopsies before and after antiviral therapy were enrolled for analysis of the association of fibrotic changes with HCC.
Results
Eighteen (6.8%) of the 265 patients developed HCC over 1931 person-years. Cox regression analysis without post-treatment fibrosis as a covariant revealed that factors predicted HCC included age (hazard ratio [HR]/confidence intervals [CI] 1.07/1.01–1.13, p = 0.01), male gender (HR/CI 4.57/1.45–14.36, p = 0.009), diabetes (HR/CI 3.60/1.32–9.85, p = 0.01) and pretreatment advanced fibrosis (HR/CI 2.73/1.05–7.07, p = 0.039). Advanced fibrosis in post-treatment status replaced pretreatment fibrosis as the most critical determinant of HCC when it was included for analysis (HR/CI 3.53/1.34–9.30, p = 0.01). The incidences of HCC among patients with fibrotic modification from F0–2 to F0–2, F34 to F0–2, F0–2 to F34 and F34 to F34 were 0.41%, 0.84%, 1.68%, and 3.05%, respectively (p = 0.004). Compared to patients whose fibrotic stage remained at F0–2 before and after treatment, the HCC risk decreased and did not differ among those whose fibrotic stage improved from F34 to F0–2. However, HCC risk increased significantly and gradually in patients whose fibrotic stages changed from F0–2 to F34 (HR/CI 4.13/1.11–15.36, p = 0.035) and whose fibrotic stages remained at F34 before and after treatment (HR/CI 7.47/2.37–23.55, p = 0.001) (trend p = 0.003).
Conclusions
Post-treatment fibrotic modifications overwhelmed pretreatment fibrotic statuses in predicting HCC.
Similar content being viewed by others
Abbreviations
- ALT:
-
Alanine aminotransferase
- AST:
-
Aspartate aminotransferase
- CHC:
-
Chronic hepatitis C
- DM:
-
Diabetes mellitus
- HCV:
-
Hepatitis C virus
- IL-28B:
-
Interleukin 28B
- SVR:
-
Sustained virological response
- SNP:
-
Single-nucleotide polymorphism
- HCC:
-
Hepatocellular carcinoma
References
Blach S, Zeuzem S, Manns M, Altraif I, Duberg AS, Muljono DH, Waked I, Alavian SM, Lee MH, Negro F, Abaalkhail F. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017;2(3):161–176
MohdHanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology (Baltimore, Md.) 2013;57(4):1333–1342
Davila JA, Morgan RO, Shaib Y, et al. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004;127(5):1372–1380
Huang CF, Yeh ML, Huang CI, et al. Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance. Oncotarget 2017;8(27):43925–43933
Huang CF, Yeh ML, Huang CY, et al. Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapy. Medicine 2016;95(27):e4157
Huang CF, Yeh ML, Tsai PC, et al. Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication. J Hepatol 2014;61(1):67–74
Morgan RL, Baack B, Smith BD, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013;158(5 Pt 1):329–337
Huang CF, Huang CY, Yeh ML, et al. Genetics variants and serum levels of MHC class I chain-related A in predicting hepatocellular carcinoma development in chronic hepatitis C patients post antiviral treatment. EBioMedicine 2017;15:81–89
Yu ML, Huang CF, Yeh ML, et al. Time-degenerative factors and the risk of hepatocellular carcinoma after antiviral therapy among hepatitis C virus patients: a model for prioritization of treatment. Clin Cancer Res 2017;23(7):1690–1697
Matsuura K, Sawai H, Ikeo K, et al. Genome-wide association study identifies TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus infection. Gastroenterology 2017;152(6):1383–1394
Yu ML, Lin SM, Lee CM, et al. A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. Hepatology (Baltimore, Md.) 2006;44(5):1086–1097
Asahina Y, Tsuchiya K, Nishimura T, et al. Alpha-fetoprotein levels after interferon therapy and risk of hepato carcinogenesis in chronic hepatitis C. Hepatology (Baltimore, Md.) 2013;58(4):1253–1262
Yeh ML, Huang CI, Huang CF, et al. Post-treatment alpha fetoprotein and platelets predict hepatocellular carcinoma development in dual-infected hepatitis B and C patients after eradication of hepatitis C. Oncotarget 2018;9(15):12240–12249
Wu CK, Chang KC, Hung CH, et al. Dynamic alpha-fetoprotein, platelets and AST-to-platelet ratio index predict hepatocellular carcinoma in chronic hepatitis C patients with sustained virological response after antiviral therapy. J Antimicrob Chemother 2016;71(7):1943–1947
Lee YA, Friedman SL. Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? Antiviral Res 2014;107:23–30
Omata M, Kanda T, Wei L, et al. APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatol Int 2016;10(5):681–701
Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology (Baltimore, Md.) 2018;67(1):358–380
Omata M, Cheng AL, Kokudo N, et al. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017;11(4):317–370
Okamoto H, Tokita H, Sakamoto M, et al. Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. J Gen Virol 1993;74(Pt 11):2385–2390
Vermehren J, Yu ML, Monto A, et al. Multi-center evaluation of the Abbott RealTime HCV assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C. J Clin Virol 2011;52(2):133–137
Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991;13(3):372–374
Huang CF, Yeh ML, Huang JF, et al. Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1. Antiviral Res 2012;93(2):239–244
Huang CF, Huang JF, Yang JF, et al. Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. J Hepatol 2012;56(1):34–40
Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122(5):1303–1313
van der Meer AJ, Berenguer M. Reversion of disease manifestations after HCV eradication. J Hepatol 2016;65(1 Suppl):S95–S108
van der Meer AJ, Feld JJ, Hofer H, et al. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol 2017;66(3):485–493
Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132(7):517–524
Facciorusso A, Del Prete V, Turco A, et al. Long-term liver stiffness assessment in hepatitis C virus patients undergoing antiviral therapy: results from a 5-year cohort study. J Gastroenterol Hepatol 2018;33(4):942–949
D’Ambrosio R, Aghemo A, Fraquelli M, et al. The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. J Hepatol 2013;59(2):251–256
EASL. EASL recommendations on treatment of hepatitis C 2018. J Hepatol 2018;69:461–511
Acknowledgements
This work was supported in part by grants from Kaohsiung Medical University (107CM-KMU-10, KMU-DK107004, MOST 106-2314-B-037-074) and Kaohsiung Medical University Hospital (KMUH106-6M02).
Author information
Authors and Affiliations
Contributions
Conception and design: M-LY. Acquisition of data: C-FH, P-CL, Y-HL, C-IH, M-LY, J-FH, Z-YL, S-CC, C-YD, and W-LC. Data analysis and interpretation: C-FH and M-LY. Manuscript drafting and critical revision: C-FH and M-LY. Approval of the final version of the manuscript: M-LY.
Corresponding author
Ethics declarations
Conflict of interest
Chung-Feng Huang, Ming-Lun Yeh, Ching-I Huang, Po-Cheng Liang, Yi-Hung Lin, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chuang, and Ming-Lung Yu declare that they have no conflict of interest.
Ethical approval
The study was conducted according to the Declaration of Helsinki. The institutional review board of the Kaohsiung Medical University Hospital approved the protocols that conformed to the guidelines of the International Conference on Harmonization for Good Clinical Practice. All patients provided written informed consent. All procedures followed the ethical standards of the responsible committee on human experimentation and the Helsinki Declaration of 1975, as revised in 2008.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Huang, CF., Yeh, ML., Huang, CI. et al. Post-treatment fibrotic modifications overwhelm pretreatment liver fibrosis in predicting HCC in CHC patients with curative antivirals. Hepatol Int 12, 544–551 (2018). https://doi.org/10.1007/s12072-018-9908-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12072-018-9908-4